Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24400Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papagoras, C. E. | en |
| dc.contributor.author | Argyropoulou, M. I. | en |
| dc.contributor.author | Voulgari, P. V. | en |
| dc.contributor.author | Vrabie, I. | en |
| dc.contributor.author | Zikou, A. K. | en |
| dc.contributor.author | Drosos, A. A. | en |
| dc.date.accessioned | 2015-11-24T19:40:46Z | - |
| dc.date.available | 2015-11-24T19:40:46Z | - |
| dc.identifier.issn | 0392-856X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24400 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Anti-Bacterial Agents/therapeutic use | en |
| dc.subject | Antibodies, Monoclonal/*adverse effects | en |
| dc.subject | Arthritis, Psoriatic/*drug therapy | en |
| dc.subject | Brucellosis/diagnosis/drug therapy/*immunology | en |
| dc.subject | Doxycycline/therapeutic use | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Immunity, Innate/immunology | en |
| dc.subject | Rifampin/therapeutic use | en |
| dc.subject | Spondylitis/*microbiology | en |
| dc.subject | Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology | en |
| dc.title | A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/19327241 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2009 | - |
| heal.abstract | A 69-year-old woman with psoriatic arthritis treated with infliximab presented with low back pain of recent onset and fever. Serological, microbiological and imaging studies revealed Brucella spondylitis at the L5-S1 level. Immunosuppressive therapy was suspended and antibiotic therapy including doxycycline and rifampicin was administered for six months. The patient responded adequately with clinical and laboratory improvement and a considerable remission of spondylitis on repeat magnetic resonance imaging scan. The pathophysiology of tumor necrosis factor (TNF) alpha in Brucellosis and the role of anti-TNFalpha therapy are discussed. | en |
| heal.journalName | Clin Exp Rheumatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
